Translation control can shape TP53-dependent cell fate.
Dario RizzottoSara ZaccaraAnnalisa RossiErik DassiAlberto IngaPublished in: Molecular & cellular oncology (2020)
The search for mechanisms underlying different cellular responses to the treatment with Nutlin-3, an MDM2 inhibitor that unleashes p53, revealed a translational control mechanism involving the RNA binding proteins PCBP2 and, particularly, DHX30. Sifting through a multi-functional p53-dependent transcriptional output, this translational control can modulate the activation of cell death pathways.